Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0
Expert consensus guidelines on immunotherapy for acute leukemia now provide clear treatment pathways for doctors managing this aggressive blood cancer.
The Society for Immunotherapy of Cancer published a clinical practice guideline on immunotherapy for acute leukemia, covering T-cell engagers, antibody-drug conjugates, and CAR-T therapies. The guideline represents consensus from major experts and is expected to directly guide treatment decisions in AML and ALL.
What the study was
- Study design
- Practice Guideline / Systematic Review
- Population
- Adults and children with acute leukemia
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
SITC practice guideline on a rapidly evolving therapy class (CAR-T, BiTE, ADC) in hematologic malignancy; publication type Practice Guideline, high relevance, broad patient impact.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.